Share on StockTwits

Medivation (NASDAQ:MDVN) is set to release its Q413 earnings data on Thursday, February 27th. Analysts expect Medivation to post earnings of ($0.08) per share and revenue of $72.68 million for the quarter.

Medivation (NASDAQ:MDVN) last released its earnings data on Thursday, January 30th. The company reported ($0.43) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.14) by $0.29. On average, analysts expect Medivation to post $-0.69 EPS for the current fiscal year and $1.24 EPS for the next fiscal year.

Shares of Medivation (NASDAQ:MDVN) opened at 86.40 on Wednesday. Medivation has a 52-week low of $41.89 and a 52-week high of $88.20. The stock has a 50-day moving average of $77. and a 200-day moving average of $64.21. The company’s market cap is $6.519 billion.

Several analysts have recently commented on the stock. Analysts at Chardan Capital reiterated a “buy” rating on shares of Medivation in a research note on Monday, February 3rd. They now have a $100.00 price target on the stock. On a related note, analysts at Citigroup Inc. raised their price target on shares of Medivation to $124.00 in a research note on Monday, February 3rd. Finally, analysts at Sanford C. Bernstein downgraded shares of Medivation from an “outperform” rating to a “market perform” rating in a research note on Monday, February 3rd. They now have a $92.00 price target on the stock, up previously from $84.00. One analyst has rated the stock with a sell rating, four have assigned a hold rating and nine have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $90.18.

In other Medivation news, CFO Clarence Patrick Machado unloaded 40,000 shares of Medivation stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $82.79, for a total transaction of $3,311,600.00. Following the sale, the chief financial officer now directly owns 30,830 shares in the company, valued at approximately $2,552,416. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Medivation, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapies.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.